FGFR3 and breast cancer: In the Metabric dataset, breast cancer patients with amplified and/or overexpressed FGFR3 (46 out of 1903, 2%) have a significant (p-value of 0.0204) worse overall survival compared to breast cancer patients without FGFR3 alterations (Fig. 10c).